{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:38:51Z","timestamp":1787564331340,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Strategic Research Foundation Grant-Aided Project for Private Universities","award":["S1101027"],"award-info":[{"award-number":["S1101027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12886-016-0202-8","type":"journal-article","created":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T06:43:10Z","timestamp":1457419390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases"],"prefix":"10.1186","volume":"16","author":[{"given":"Hiroshi","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Gosho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Zako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,8]]},"reference":[{"key":"202_CR1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/jop.2013.0179","volume":"30","author":"NS Winkler","year":"2014","unstructured":"Winkler NS, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2014;30:102\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"key":"202_CR2","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.survophthal.2008.08.010","volume":"53","author":"CB Toris","year":"2008","unstructured":"Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53:S107\u201320.","journal-title":"Surv Ophthalmol"},{"key":"202_CR3","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1167\/iovs.08-3356","volume":"50","author":"YH Ooi","year":"2009","unstructured":"Ooi YH, Oh DJ, Rhee DJ. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells. Invest Ophthalmol Vis Sci. 2009;50:5259\u201365.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"202_CR4","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1124\/pr.112.007088","volume":"65","author":"DF Woodward","year":"2013","unstructured":"Woodward DF, Wang JW, Poloso NJ. Recent progress in prostaglandin F2\u03b1 ethanolamide (prostamide F2\u03b1) research and therapeutics. Pharmacol Rev. 2013;65:1135\u201347.","journal-title":"Pharmacol Rev"},{"key":"202_CR5","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0039-6257(97)80003-3","volume":"41","author":"DF Woodward","year":"1997","unstructured":"Woodward DF, Regan JW, Lake S, Ocklind A. The molecular biology and ocular distribution of prostanoid receptors. Surv Ophthalmol. 1997;41:S15\u201321.","journal-title":"Surv Ophthalmol"},{"key":"202_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.2006.00001.x","volume":"24","author":"N Ishida","year":"2006","unstructured":"Ishida N, Odani-Kawabata N, Shimazaki A, Hara H. Prostanoids in the therapy of glaucoma. Cardiovasc Drug Rev. 2006;24:1\u201310.","journal-title":"Cardiovasc Drug Rev"},{"key":"202_CR7","doi-asserted-by":"crossref","unstructured":"Oh DJ, Martin JL, Williams AJ, Peck RE, Pokorny C, Russell P, Birk DE, Rhee DJ. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost. Invest Ophthalmol Vis Sci. 2006;47:953\u201363.","DOI":"10.1167\/iovs.05-0516"},{"key":"202_CR8","volume-title":"Duane\u2019s ophthalmology on CD-ROM","author":"B Gablet","year":"2006","unstructured":"Gablet B, Kiland JA, Tian B, Kaufman PL, Aqueous humor: Secretion and dynamics, Kiel JW. Physiology of the eye and visual system. In: Tasman W, Jaeger EA, editors. Duane\u2019s ophthalmology on CD-ROM. 2006th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. http:\/\/www.eyecalcs.com\/DWAN\/index.html .","edition":"2006"},{"key":"202_CR9","doi-asserted-by":"crossref","unstructured":"Yamada H, Yoneda M, Inaguma S, Watanabe D, Banno S, Yoshikawa K, Mizutani K, Iwaki M, Zako M. Infliximab counteracts tumor necrosis factor-\u03b1-enhanced induction of matrix metalloproteinases that degrade claudin and occludin in non-pigmented ciliary epithelium. Biochem Pharmacol. 2013;85:1770\u201382.","DOI":"10.1016\/j.bcp.2013.04.006"},{"key":"202_CR10","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1167\/iovs.06-0036","volume":"47","author":"DJ Oh","year":"2006","unstructured":"Oh DJ, Martin JL, Williams AJ, Russell P, Birk DE, Rhee DJ. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2006;47:3887\u201395.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"202_CR11","first-page":"2772","volume":"38","author":"RN Weinreb","year":"1997","unstructured":"Weinreb RN, Kashiwagi K, Kashiwagi F, Tsukahara S, Lindsey JD. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997;38:2772\u201380.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"202_CR12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/exer.1998.0508","volume":"67","author":"A Ocklind","year":"1998","unstructured":"Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179\u201391.","journal-title":"Exp Eye Res"},{"key":"202_CR13","doi-asserted-by":"crossref","unstructured":"el-Shabrawi Y, Eckhardt M, Berghold A, Faulborn J, Auboeck L, Mangge H, Ardjomand N. Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone. Eye (Lond). 2000;14:375\u201383.","DOI":"10.1038\/eye.2000.92"},{"key":"202_CR14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3109\/02713689609017628","volume":"15","author":"JD Lindsey","year":"1996","unstructured":"Lindsey JD, Kashiwagi K, Boyle D, Kashiwagi F, Firestein GS, Weinreb RN. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 1996;15:869\u201375.","journal-title":"Curr Eye Res"},{"key":"202_CR15","first-page":"3705","volume":"43","author":"TL Anthony","year":"2002","unstructured":"Anthony TL, Lindsey JD, Weinreb RN. Latanoprost\u2019s effects on TIMP-1 and TIMP-2 expression in human ciliary muscle cells. Invest Ophthalmol Vis Sci. 2002;43:3705\u201311.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"202_CR16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF02850157","volume":"21","author":"ST Simmons","year":"2004","unstructured":"Simmons ST, Dirks MS, Noecker RJ. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. Adv Ther. 2004;21:247\u201362.","journal-title":"Adv Ther"},{"key":"202_CR17","doi-asserted-by":"crossref","unstructured":"Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM, Bimatoprost\/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55\u201363.","DOI":"10.1016\/S0002-9394(02)01827-5"},{"key":"202_CR18","first-page":"1967","volume":"8","author":"A Alm","year":"2014","unstructured":"Alm A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014;8:1967\u201385.","journal-title":"Clin Ophthalmol"},{"key":"202_CR19","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0002-9394(03)00098-9","volume":"135","author":"RK Parrish","year":"2003","unstructured":"Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688\u2013703.","journal-title":"Am J Ophthalmol"},{"key":"202_CR20","first-page":"691","volume":"27","author":"Y Fukano","year":"2010","unstructured":"Fukano Y, Odani-Kawabata N, Nakamura M, Kawazu K. Intraocular penetration and intraocular pressure-lowering effect of new formulation 0.0015\u00a0% tafluprost ophthalmic solution with reduced benzalkonium chloride. Atarashii Ganka. 2010;27:691\u20134.","journal-title":"Atarashii Ganka"},{"key":"202_CR21","doi-asserted-by":"crossref","unstructured":"Camras CB, Toris CB, Sjoquist B, Milleson M, Thorngren JO, Hejkal TW, Patel N, Barnett EM, Smolyak R, Hasan SF, Hellman C, Meza JL, Wax MB, Stjernschantz J. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology. 2004;111:2193\u20138.","DOI":"10.1016\/j.ophtha.2004.06.028"},{"key":"202_CR22","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0039-6257(02)00302-8","volume":"47","author":"B Sj\u00f6quist","year":"2002","unstructured":"Sj\u00f6quist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47:S6\u201312.","journal-title":"Surv Ophthalmol"},{"key":"202_CR23","doi-asserted-by":"crossref","unstructured":"English WR, Puente XS, Freije JM, Knauper V, Amour A, Merryweather A, Lopez-Otin C, Murphy G. Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2. J Biol Chem. 2000;275:14046\u201355.","DOI":"10.1074\/jbc.275.19.14046"},{"key":"202_CR24","doi-asserted-by":"crossref","unstructured":"Ohno-Jinno A, Isogai Z, Yoneda M, Kasai K, Miyaishi O, Inoue Y, Kataoka T, Zhao JS, Li H, Takeyama M, Keene DR, Sakai LY, Kimata K, Iwaki M, Zako M. Versican and fibrillin-1 form a major hyaluronan-binding complex in the ciliary body. Invest Ophthalmol Vis Sci. 2008;49:2870\u20137.","DOI":"10.1167\/iovs.07-1488"},{"key":"202_CR25","doi-asserted-by":"crossref","unstructured":"Muir EM, Adcock KH, Morgenstern DA, Clayton R, von Stillfried N, Rhodes K, Ellis C, Fawcett JW, Rogers JH. Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res Mol Brain Res. 2002;100:103\u201317.","DOI":"10.1016\/S0169-328X(02)00132-8"},{"key":"202_CR26","doi-asserted-by":"crossref","unstructured":"Ashworth JL, Murphy G, Rock MJ, Sherratt MJ, Shapiro SD, Shuttleworth CA, Kielty CM. Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling. Biochem J. 1999;340:171\u201381.","DOI":"10.1042\/bj3400171"},{"key":"202_CR27","doi-asserted-by":"crossref","unstructured":"Takeyama M, Yoneda M, Takeuchi M, Isogai Z, Ohno-Jinno A, Kataoka T, Li H, Sugita I, Iwaki M, Zako M. Increase in matrix metalloproteinase-2 level in the chicken retina after laser photocoagulation. Lasers Surg Med. 2010;42:433\u201341.","DOI":"10.1002\/lsm.20931"},{"key":"202_CR28","first-page":"3299","volume":"41","author":"A Vaughan-Thomas","year":"2000","unstructured":"Vaughan-Thomas A, Gilbert SJ, Duance VC. Elevated levels of proteolytic enzymes in the aging human vitreous. Invest Ophthalmol Vis Sci. 2000;41:3299\u2013304.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"202_CR29","first-page":"1256","volume":"39","author":"MA Paz De La","year":"1998","unstructured":"De La Paz MA, Itoh Y, Toth CA, Nagase H. Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthalmol Vis Sci. 1998;39:1256\u201360.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"202_CR30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1076\/ceyr.17.2.132.5610","volume":"17","author":"JJ Plantner","year":"1998","unstructured":"Plantner JJ, Smine A, Quinn TA. Matrix metalloproteinases and metalloproteinase inhibitors in human interphotoreceptor matrix and vitreous. Curr Eye Res. 1998;17:132\u201340.","journal-title":"Curr Eye Res"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-016-0202-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T03:52:28Z","timestamp":1498276348000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-2415\/16\/26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,8]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["202"],"URL":"https:\/\/doi.org\/10.1186\/s12886-016-0202-8","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,8]]},"article-number":"26"}}